🇺🇸 FDA
Pipeline program

NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED

Phase 3 small_molecule active

Quick answer

NIVOLUMAB, GEMCITABINE, TEPMETKO 225 mg film-coated tablets, PACLITAXEL, DOCETAXEL, ATEZOLIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, PEMETREXED for Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer is a Phase 3 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CERO THERAPEUTICS HOLDINGS, INC.
Indication
Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials